SARS-CoV-2 Omicron BA.2.75 variant may be much more infective than preexisting variants
Covid19-Sources
Unravelling the role of the mandatory use of face covering masks for the control of SARS-CoV-2 in schools: a quasi-experimental study nested in a population-based cohort in Catalonia (Spain)
COVID-19 Increasing Stroke Risks in People of All Ages
Twitter 3 good reasons to get your kids vaccinated against covid: ▶️ Risk of hospitalization reduced by 83% ▶️ Risk of MIS-C (multisystemic inflammatory syndrome) reduced by 90% ▶️ Immunity generated by vaccination (alone or after an infection) immunity generated by 1-2 infections
Jan Hartmann on Twitter
Global patterns of antigen receptor repertoire disruption across adaptive immune compartments in COVID-19
Distinguishing features of Long COVID identified through immune profiling
Prof. Akiko Iwasaki on Twitter
Clinical and Genetic Risk Factors for Acute Incident VTE in Ambulatory Patients With COVID-19
Eric Topol on Twitter
Comparing the COVID-19 Vaccines: How Are They Different?
The Novavax vaccine against COVID-19: What you need to know
Eric Feigl-Ding on Twitter
Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients
This analysis of 2-year retrospective cohort studies of individuals diagnosed with COVID-19 showed that the increased incidence of mood and anxiety disorders was transient, with no overall excess of these diagnoses compared with other respiratory infections. In contrast, the increased risk of psychotic disorder, cognitive deficit, dementia, and epilepsy or seizures persisted throughout. The differing trajectories suggest a different pathogenesis for these outcomes. Children have a more benign overall profile of psychiatric risk than do adults and older adults, but their sustained higher risk of some diagnoses is of concern. The fact that neurological and psychiatric outcomes were similar during the delta and omicron waves indicates that the burden on the health-care system might continue even with variants that are less severe in other respects. Our findings are relevant to understanding individual-level and population-level risks of neurological and psychiatric disorders after SARS-CoV-2 infection and can help inform our responses to them.
We identified 1 487 712 patients with a recorded diagnosis of COVID-19 during the study period, of whom 1 284 437 (185 748 children, 856 588 adults, and 242 101 older adults; overall mean age 42·5 years [SD 21·9]; 741 806 [57·8%] were female and 542 192 [42·2%] were male) were adequately matched with an equal number of patients with another respiratory infection. The risk trajectories of outcomes after SARS-CoV-2 infection in the whole cohort differed substantially. While most outcomes had HRs significantly greater than 1 after 6 months (with the exception of encephalitis; Guillain-Barré syndrome; nerve, nerve root, and plexus disorder; and parkinsonism), their risk horizons and time to equal incidence varied greatly. Risks of the common psychiatric disorders returned to baseline after 1–2 months (mood disorders at 43 days, anxiety disorders at 58 days) and subsequently reached an equal overall incidence to the matched comparison group (mood disorders at 457 days, anxiety disorders at 417 days). By contrast, risks of cognitive deficit (known as brain fog), dementia, psychotic disorders, and epilepsy or seizures were still increased at the end of the 2-year follow-up period. Post-COVID-19 risk trajectories differed in children compared with adults: in the 6 months after SARS-CoV-2 infection, children were not at an increased risk of mood (HR 1·02 [95% CI 0·94–1·10) or anxiety (1·00 [0·94–1·06]) disorders, but did have an increased risk of cognitive deficit, insomnia, intracranial haemorrhage, ischaemic stroke, nerve, nerve root, and plexus disorders, psychotic disorders, and epilepsy or seizures (HRs ranging from 1·20 [1·09–1·33] to 2·16 [1·46–3·19]). Unlike adults, cognitive deficit in children had a finite risk horizon (75 days) and a finite time to equal incidence (491 days). A sizeable proportion of older adults who received a neurological or psychiatric diagnosis, in either cohort, subsequently died, especially those diagnosed with dementia or epilepsy or seizures. Risk profiles were similar just before versus just after the emergence of the alpha variant (n=47 675 in each cohort). Just after (vs just before) the emergence of the delta variant (n=44 835 in each cohort), increased risks of ischaemic stroke, epilepsy or seizures, cognitive deficit, insomnia, and anxiety disorders were observed, compounded by an increased death rate. With omicron (n=39 845 in each cohort), there was a lower death rate than just before emergence of the variant, but the risks of neurological and psychiatric outcomes remained similar.
Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate
Ralf Wittenbrink on Twitter
SARS CoV-2 detected in neonatal stool remote from maternal COVID-19 during pregnancy
SARS-CoV-2 and the central nervous system: Emerging insights into hemorrhage-associated neurological consequences and therapeutic considerations - PubMed
Covid 19 may accelerate brain aging increase neurological risk
Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study
Gout and the COVID-19 pandemic - PubMed
Corona: Antivirale Therapie kann Virus-Mutationen fördern
A reinfection red flag
Heart disease after COVID: what the data say´s
Non-SARS Coronaviruses in Individuals with Psychiatric Disorders
The schizophrenia group had significantly increased levels of antibodies to the seasonal Coronaviruses OC43 and NL63. This group also had increased odds of having elevated antibody levels to OC43. The major depression group showed a significantly lower level of antibodies to Coronavirus 229E. There were no significant differences between any of the psychiatric groups and the comparison group in the levels of antibodies to seasonal Coronaviruses 229E or HKU1.
Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope
Travel-associated SARS-CoV-2 transmission documented with whole genome sequencing following a long-haul international flight
Is SARS-CoV-2 an oncogenic virus?
DEFINE_ME